Clinical Trials

Study Title:
PD Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabosantinib with Nivolumab: a Phase III Trial in Metastatic Untreated Renal Cell cancer (PDIGREE)

For more information about the trial above please contact the study team: Medical University of South Carolina Principal Investigator, Theodore Gourdin, at gourdith@musc.edu. Study Coordinator, Renee Tucker, at tuckerr@musc.edu. Trial opened at the following institutions: Medical University of South Carolina